![]() ![]() ![]() ![]() Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 13% annually. If achieved, this would be a much better result than the 81% annual decline over the past five years. One thing stands out from these estimates, which is that Spectrum Pharmaceuticals is forecast to grow faster in the future than it has in the past, with revenues expected to display 4x annualised growth until the end of 2023. Of course, another way to look at these forecasts is to place them into context against the industry itself. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. There are some variant perceptions on Spectrum Pharmaceuticals, with the most bullish analyst valuing it at US$4.00 and the most bearish at US$0.75 per share. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The average price target fell 15% to US$2.65, with the analysts clearly concerned about the weaker revenue outlook and expectation of ongoing losses. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$55.9m and losses of US$0.21 per share in 2023. The loss per share is expected to greatly reduce in the near future, narrowing 46% to US$0.21. This would be a substantial 401% improvement in sales compared to the last 12 months. Following the latest results, Spectrum Pharmaceuticals' five analysts are now forecasting revenues of US$50.6m in 2023. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |